News

The two grants totaling were awarded to ExonHit by the US Secretary of Health and Human Services to support its Alzheimer’s disease and oncology research and development projects.

The Phase I trial for AC430 is a two part, placebo-controlled, single ascending, and multiple ascending dose trial in healthy volunteers. In the trial, AC430 will be administered

Eisai has submitted an application to the Japanese Ministry of Health, Labour and Welfare on 28 April 2010, seeking approval of additional twice-daily dosage and administration of Pariet

Biogen Idec will make an initial payment of $32.5m and up to $395m in contingent payments. Biogen Idec and Neurimmune said that the acquisition builds on a 2007

Colistin is an antibiotic used to treat the principal bacterial infections in cystic fibrosis (CF) patients, and Colobreathe is a novel dry powder inhaler containing Colistin developed by

Arresto develops medicines that target enzymes involved in the synthesis of the extracellular matrix, which appear to play a role in the etiology of a variety of fibrotic

VistaGen’s initial AV-101 Phase 1 clinical trial was a randomized, double-blind, placebo-controlled study designed to evaluate the safety and pharmacokinetics of single doses of AV-101 in two cohorts

For the study, David Myszka, founder of Biosensor Tools and director of the Center for Biomolecular Interaction Analysis at the University of Utah, used surface plasmon resonance (SPR)

In the first two cohorts of healthy volunteers, the safety, tolerability, pharmacokinetics and optimal formulation of the candidate compound will be evaluated during a placebo controlled dose escalation.